Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery |
| |
Authors: | Diemunsch P; Schoeffler P; Bryssine B; Cheli-Muller L E; Lees J; McQuade B A; Spraggs C F |
| |
Institution: | Hospital Civil, Strasbourg, France; Hotel-Dieu, Clermont-Ferrand, France; Hotel-Dieu, Lyon, France; Laboratoire Glaxo Wellcome SAS, Paris, France; Department of Clinical Statistics and Department of Oncology and Emesis Clinical Research, Glaxo Wellcome Research and Development, Greenford, Middlesex UB6 OHE, UK |
| |
Abstract: | In this double-blind, randomized, parallel group study, we have
investigated the antiemetic activity of the potent and selective NK1
receptor antagonist GR205171 25 mg i.v. compared with placebo in the
treatment of established postoperative nausea and vomiting (PONV) in
patients after major gynaecological surgery performed under general
anaesthesia. The incidence of PONV in the study population was 65%.
Thirty-six patients were treated with placebo or GR205171 (18 patients per
group). GR205171 produced greater control of PONV than placebo over the
24-h assessment period. The stimuli for emesis after PONV are
multifactorial and the efficacy of GR205171 in this study supports the
broad spectrum potential for NK1 receptor antagonists in the management of
postoperative emesis. GR205171 was well tolerated and no adverse events
were reported that would preclude the further development of this agent.
|
| |
Keywords: | |
本文献已被 Oxford 等数据库收录! |
|